奎硫平辅助治疗抑郁症的临床疗效及安全性研究

目的探讨奎硫平合并抗抑郁药治疗抑郁症的疗效及安全性。方法将60名抑郁症患者随机分为合并奎硫平治疗组和对照组，合并奎硫平治疗组在原抗抑郁药物治疗的基础上合并使用奎硫平，对照组继续使用原抗抑郁药物，疗程为4周。入组时及入组第1、2、3、4周末对患者进行汉密顿抑郁量表（HAMD-17）、汉密顿焦虑量表（HAMA）、副反应量表（TESS）评定。结果合并奎硫平组共完成25例，1例在加用50mg奎硫平后出现双下肢水肿，故退出研究。1例在治疗过程中出现严重精神病性症状，在治疗第1周由研究者中止研究。2例在第2周脱落，1例在第四周时脱落。治疗第1周末起两组HAMD、HAMA总分差异有统计学意义（P〈0．01），合并奎硫平组低于对照组。研究组总有效率为83．3％，痊愈与显效占56．7％，对照组分别为50％和20％。研究组与对照组疗效存在显著差异。研究组出现不良反应共13例（43．3％），1例因服用50mg奎硫平后出现双下肢水肿而退出研究，其余均为可疑或极轻到中度。对照组共12例（40％）出现不良反应。结论奎硫平合并抗抑郁药治疗抑郁症是1种有效且相对安全的治疗方法。

Efficacy and safety of quetiapine augmentation of antidepressants on depression

Objective: To explore the effects of quetiapine augmentation of antidepressants on depression.Methods: 60 patients with depression were assigned randomly to either of the two groups: quetiapine plus ongoing antidepressant or antidepressant alone.They were estimated with HAMD,HAMA,and TESS at baseline and every one week subsequently.The study lasted for 4 weeks.Results:There were significant difference in the scores of HAMD and HAMA between the two groups since one week after the treatment(P<0.01).83.3% is responded to the augmented treatment while 50% to the mono-therapy,quetiapine augmentation produced greater improvement than antidepressant mono-therapy(p<0.01).The total incidence rate of side effect(by case) of combining-treatment was 43.3%,one patient quit the research because of lower limbs oedema after took 50mg qutiapine.Conclusion:Quetiapine may be a useful and safe adjunct to antidepressant on depression.